Literature DB >> 29958847

Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.

J Uthoff1, F A De Stefano2, K Panzer3, B W Darbro3, T S Sato2, R Khanna4, D E Quelle5, D K Meyerholz6, J Weimer7, J C Sieren8.   

Abstract

BACKGROUND: This study explores whether objective, quantitative radiomic biomarkers derived from magnetic resonance (MR), positron emission tomography (PET), and computed tomography (CT) may be useful in reliably distinguishing malignant peripheral nerve sheath tumors (MPNST) from benign plexiform neurofibromas (PN).
METHODS: A registration and segmentation pipeline was established using a cohort of NF1 patients with histopathological diagnosis of PN or MPNST, and medical imaging of the PN including MR and PET-CT. The corrected MR datasets were registered to the corresponding PET-CT via landmark-based registration. PET standard-uptake value (SUV) thresholds were used to guide segmentation of volumes of interest: MPNST-associated PET-hot regions (SUV≥3.5) and PN-associated PET-elevated regions (2.0<SUV<3.5). Quantitative imaging features were extracted from the MR, PET, and CT data and compared for statistical differences. Intensity histogram features included (mean, media, maximum, variance, full width at half maximum, entropy, kurtosis, and skewness), while image texture was quantified using Law's texture energy measures, grey-level co-occurrence matrices, and neighborhood grey-tone difference matrices.
RESULTS: For each of the 20 NF1 subjects, a total of 320 features were extracted from the image data. Feature reduction and statistical testing identified 9 independent radiomic biomarkers from the MR data (4 intensity and 5 texture) and 4 PET (2 intensity and 2 texture) were different between the PET-hot versus PET-elevated volumes of interest.
CONCLUSIONS: Our data suggests imaging features can be used to distinguish malignancy in NF1-realted tumors, which could improve MPNST risk assessment and positively impact clinical management of NF1 patients.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; Malignant peripheral nerve sheath tumor; Plexiform neurofibroma; Positron emission tomography; Quantitative feature extraction

Mesh:

Substances:

Year:  2018        PMID: 29958847      PMCID: PMC6310110          DOI: 10.1016/j.neurad.2018.05.006

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  38 in total

1.  Parametric estimate of intensity inhomogeneities applied to MRI.

Authors:  M Styner; C Brechbühler; G Székely; G Gerig
Journal:  IEEE Trans Med Imaging       Date:  2000-03       Impact factor: 10.048

2.  Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging.

Authors:  Jeffrey Solomon; Katherine Warren; Eva Dombi; Nicholas Patronas; Brigitte Widemann
Journal:  Comput Med Imaging Graph       Date:  2004-07       Impact factor: 4.790

3.  Influence of MRI acquisition protocols and image intensity normalization methods on texture classification.

Authors:  G Collewet; M Strzelecki; F Mariette
Journal:  Magn Reson Imaging       Date:  2004-01       Impact factor: 2.546

4.  Engineering and algorithm design for an image processing Api: a technical report on ITK--the Insight Toolkit.

Authors:  Terry S Yoo; Michael J Ackerman; William E Lorensen; Will Schroeder; Vikram Chalana; Stephen Aylward; Dimitris Metaxas; Ross Whitaker
Journal:  Stud Health Technol Inform       Date:  2002

5.  [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

Authors:  Victoria S Warbey; Rosalie E Ferner; Joel T Dunn; Eduardo Calonje; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

6.  Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.

Authors:  Matthias R Benz; Johannes Czernin; Sarah M Dry; William D Tap; Martin S Allen-Auerbach; David Elashoff; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

7.  Use of the CT component of PET-CT to improve PET-MR registration: demonstration in soft-tissue sarcoma.

Authors:  Edward J Somer; Nigel A Benatar; Michael J O'Doherty; Mike A Smith; Paul K Marsden
Journal:  Phys Med Biol       Date:  2007-11-12       Impact factor: 3.609

8.  Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI.

Authors:  Akihiko Matsumine; K Kusuzaki; T Nakamura; S Nakazora; R Niimi; T Matsubara; K Uchida; T Murata; I Kudawara; T Ueda; N Naka; N Araki; M Maeda; A Uchida
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-20       Impact factor: 4.553

9.  Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.

Authors:  Wenli Cai; Ara Kassarjian; Miriam A Bredella; Gordon J Harris; Hiroyuki Yoshida; Victor F Mautner; Ralph Wenzel; Scott R Plotkin
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

10.  [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.

Authors:  R E Ferner; J F Golding; M Smith; E Calonje; W Jan; V Sanjayanathan; M O'Doherty
Journal:  Ann Oncol       Date:  2007-10-11       Impact factor: 32.976

View more
  5 in total

1.  PET/MRI Improves Management of Children with Cancer.

Authors:  Lucia Baratto; K Elizabeth Hawk; Lisa States; Jing Qi; Sergios Gatidis; Louise Kiru; Heike E Daldrup-Link
Journal:  J Nucl Med       Date:  2021-10       Impact factor: 10.057

2.  Machine learning approach to differentiation of peripheral schwannomas and neurofibromas: A multi-center study.

Authors:  Michael Zhang; Elizabeth Tong; Sam Wong; Forrest Hamrick; Maryam Mohammadzadeh; Vaishnavi Rao; Courtney Pendleton; Brandon W Smith; Nicholas F Hug; Sandip Biswal; Jayne Seekins; Sandy Napel; Robert J Spinner; Mark A Mahan; Kristen W Yeom; Thomas J Wilson
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

3.  Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Authors:  Inka Ristow; Frederic Madesta; Lennart Well; Farzad Shenas; Felicia Wright; Isabel Molwitz; Said Farschtschi; Peter Bannas; Gerhard Adam; Victor F Mautner; René Werner; Johannes Salamon
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

4.  Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.

Authors:  Shivani Ahlawat; K Ina Ly; Laura M Fayad; Michael J Fisher; Andrés J Lessing; Dale J Berg; Johannes M Salamon; Victor-Felix Mautner; Dusica Babovic-Vuksanovic; Eva Dombi; Gordon Harris; Scott R Plotkin; Jaishri Blakeley
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

5.  Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.

Authors:  Johanna Uthoff; Jared Larson; Takashi S Sato; Emily Hammond; Kimberly E Schroeder; Frank Rohret; Christopher S Rogers; Dawn E Quelle; Benjamin W Darbro; Rajesh Khanna; Jill M Weimer; David K Meyerholz; Jessica C Sieren
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.